TCA cycle inhibition by CPI-613 increases chemo sensitivity in older AML patients

Bookmark and Share
Published: 6 Dec 2016
Views: 2711
Rating:
Save
Dr Timothy Pardee - Wake Forest Baptist Medical Center, Winston-Salem, USA

Dr Pardee speaks with ecancertv at ASH 2016 about CPI-613, a novel agent which inhibits the citric acid cycle (TCA).

He describes how blocking metabolic pathways with CPI-613 starves leukaemia cells of energy and reduces treatment resistance, especially when combined with cytarabine (ara-c) for older patients with relapse acute myeloid leukaemia.

Dr Pardee summarises RNA-seq analysis of patient bone marrow as highlighting a possible gene signature of best responders.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.